Online inquiry

IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1099MR)

This product GTTS-WQ1099MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1099MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11483MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ4216MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ15096MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ15750MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ2745MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ4088MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ9430MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ11893MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW